Are Lloyds Banking Group PLC And GlaxoSmithKline plc Bargain Buys For 2016?

Why Lloyds Banking Group PLC (LON:LLOY) and GlaxoSmithKline plc (LON:GSK) could reverse recent losses and beat the market in 2016.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Lloyds Banking Group (LSE: LLOY) and GlaxoSmithKline (LSE: GSK) may beat the FTSE 100 this year, but both stocks look likely to end the year lower than they started. Will they bounce back next year?

GlaxoSmithKline: On the rise

Shares in Glaxo are now down by nearly 25% from the highs seen in 2013. In fairness, this weakness has been justified by the firm’s recent financial performance, which has been disappointing.

Glaxo’s post-tax profits plunged from £5.436bn in 2013 to just £2.756bn in 2014 as the impact of patent losses on key products affected sales.

However, the situation does seem to be improving. Glaxo has now completed a major asset swap with Novartis and last week announced a new deal to acquire additional HIV products. Analysts expect full-year profits to rise by 34% to £3.691bn this year, and by a further 11% to £4.099bn in 2016.

The firm has managed to avoid cutting its dividend so far and currently offers a prospective yield of 6.1% for 2016. Big long-term backers of GlaxoSmithKline, such as star fund manager Neil Woodford, have been buying more shares this year.

Mr Woodford’s view is that short-term headwinds are overshadowing the much greater long-term earning power of Glaxo’s portfolio. This is a view I share.

For investors looking for long-term income and growth, I think that now could prove to be a good time to buy GlaxoSmithKline.

Lloyds: Stock overhang

I believe that Lloyds investors are suffering from a problem that more commonly affects shareholders in small cap companies – a stock overhang.

The overhang comes in the form of the government, which is gradually pumping its Lloyds shares back into the market. Since the end of May, the Treasury has sold 9% of Lloyds shares. That’s equivalent to £5.2bn worth of shares at today’s price.

This means that big institutional buyers of the stock have been guaranteed a good supply of Lloyds shares, without pushing up the price.

However, the share sale has been paused recently as Lloyds shares have been selling below 73.6p. This is the price at which the government bailed out Lloyds in 2008. The bankers handling the sale have been told only to sell Lloyds stock when the price is above this level.

I suspect that this requirement means Lloyds’ share price will find support at around 70p, as the volume of shares available for institutions to buy is much lower now that the government isn’t selling.

However, I also suspect that Lloyds shares won’t rise much above 73.6p until the government has sold all of its shares, which it hopes to do in 2016.

That’s why I believe now could be a good time to buy. At today’s price of 72p, Lloyds offers a prospective yield of 5.1% for 2016, and a modest forecast P/E of 9.5. The shares are supported by a book value of 68p and by 55p per share of tangible assets.

In my view Lloyds currently offers more upside potential than downside risk, and could prove a profitable buy for 2016.

Roland Head owns shares of GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Black woman using smartphone at home, watching stock charts.
Investing Articles

Are investors running scared of Babcock and BAE Systems shares?

BAE Systems shares have had a brilliant run, and other UK defence stocks have been flying too. But Harvey Jones…

Read more »

Mature black woman at home texting on her cell phone while sitting on the couch
Investing Articles

As the FTSE 100 falls, savvy investors are looking for stocks to buy for the rebound

Many FTSE stocks have now fallen 10% or more from their 2026 highs. For long-term investors, exciting opportunities are emerging.

Read more »

Portrait Of Senior Couple Climbing Hill On Hike Through Countryside In Lake District UK Together
Investing Articles

Should investors consider buying resilient Admiral Group and Tesco shares as markets wobble?

Harvey Jones is impressed by how Tesco shares have held up in the current market volatility, while Admiral has been…

Read more »

DIVIDEND YIELD text written on a notebook with chart
Investing Articles

Down 15% in a month and yielding 7.5%! Should I buy even more of my favourite dividend stock?

Harvey Jones says this brilliant FTSE 100 dividend stock is suddenly cheaper due to recent market volatility. And the yield…

Read more »

Abstract bull climbing indicators on stock chart
Growth Shares

3 growth shares for an ISA that have beaten the FTSE 100 for the past 5 years

Jon Smith points out several growth shares that have outperformed the broader market over a long period of time, with…

Read more »

Calendar showing the date of 5th April on desk in a house
Investing Articles

Time’s running out for our 2025/26 Stocks and Shares ISA plans!

Never mind the stock market wobble, it's time to turn our attention to our Stocks and Shares ISA investments for…

Read more »

UK financial background: share prices and stock graph overlaid on an image of the Union Jack
Investing Articles

What might Warren Buffett think about today’s stock market?

Middle East conflict has given the UK stock market a bit of a hammering. But in the long-term scheme of…

Read more »

Man riding the bus alone
Dividend Shares

How big does my ISA need to be to make £2.5k in monthly passive income?

Jon Smith points out the key factors that go into building a dividend portfolio for passive income, and reviews one…

Read more »